BioAtla Inc [BCAB] stock is trading at $3.44, down -0.58%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BCAB shares have gain 42.74% over the last week, with a monthly amount glided 28.84%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, March 2024, BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress. In a post published today on Yahoo Finance, CAB-CTLA-4 (BA3071) Phase 1 study cleared dose-limiting toxicity (DLT) observation period with 700 mg (10 mg/kg); initial Phase 2 monotherapy data readout anticipated in 2Q 2024 and in combination with pembrolizumab in 2H 2024.
From an analyst’s perspective:
BioAtla Inc [NASDAQ: BCAB] stock has seen the most recent analyst activity on September 15, 2022, when JMP Securities initiated its Mkt Outperform rating and assigned the stock a price target of $17. Previously, Credit Suisse downgraded its rating to Neutral on May 05, 2022, and dropped its price target to $5. On March 21, 2022, H.C. Wainwright initiated with a Buy rating and assigned a price target of $25 on the stock. ROTH Capital initiated its recommendation with a Buy and recommended $75 as its price target on June 28, 2021.
BioAtla Inc [BCAB] stock has fluctuated between $1.24 and $4.07 over the past year. BioAtla Inc [NASDAQ: BCAB] shares were valued at $3.44 at the most recent close of the market.
Analyzing the BCAB fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.02, Equity is -1.09 and Total Capital is -1.42. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.33 points at the first support level, and at 3.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.55, and for the 2nd resistance point, it is at 3.66.
BioAtla Inc [BCAB] reported earnings per share of -$0.7 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.8/share, meaning a difference of $0.1 and a surprise factor of 12.50%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.75 per share as compared to estimates of -$0.64 per share, a difference of -$0.11 representing a surprise of -17.20%.
Ratios To Look Out For
For context, BioAtla Inc’s Current Ratio is 4.11. In addition, the Quick Ratio stands at 4.11 and the Cash Ratio stands at 3.93.
Transactions by insiders
Recent insider trading involved MCBRINN SYLVIA, Director, that happened on Dec 26 ’23 when 4000.0 shares were purchased. Chief Executive Officer, SHORT JAY M PHD completed a deal on Dec 20 ’23 to buy 50000.0 shares. Meanwhile, Director STEINMAN LAWRENCE bought 20000.0 shares on Dec 19 ’23.
